|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-10-18
|
|
pubmed:abstractText |
Pioglitazone, an antihyperglycemic drug, increases plasma high-density lipoprotein (HDL)-cholesterol in patients with type 2 diabetes. The mechanisms by which pioglitazone regulate HDL levels are not clear. This study examined the effect of pioglitazone on hepatocyte apolipoprotein AI (apoA-I) and apoA-II production and HDL-protein/cholesterol ester uptake.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1524-4636
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2428-34
|
|
pubmed:meshHeading |
pubmed-meshheading:17872455-Apolipoprotein A-I,
pubmed-meshheading:17872455-Apolipoprotein A-II,
pubmed-meshheading:17872455-Cell Line, Tumor,
pubmed-meshheading:17872455-Humans,
pubmed-meshheading:17872455-Hypoglycemic Agents,
pubmed-meshheading:17872455-Lipoproteins, HDL,
pubmed-meshheading:17872455-RNA, Messenger,
pubmed-meshheading:17872455-Thiazolidinediones,
pubmed-meshheading:17872455-Up-Regulation
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha.
|
|
pubmed:affiliation |
Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, California 90822, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
